FDA接连警告,左氧氟沙星、莫西沙星还能卖吗?

2016-09-13 司徒阳明 赛柏蓝

9月8日,国家食药监总局(CFDA)的接连发布两期药物警戒快讯 。其中包括美国FDA、加拿大、英国等国家对总计11个药品进行的警示。而备受关注的是FDA对氟喹诺酮类药品的警戒说明。喹诺酮类抗生素是全球抗感染药物市场上的一个重要分支,是在头孢类抗生素之后全球抗感染市场用药量最大的药物。值得关注的是,这已经是今年FDA第二次发布针对此款药品的警戒说明。2016年5月12日,FDA发布公告,限制

9月8日,国家食药监总局(CFDA)的接连发布两期药物警戒快讯 。其中包括美国FDA、加拿大、英国等国家对总计11个药品进行的警示。而备受关注的是FDA对氟喹诺酮类药品的警戒说明。喹诺酮类抗生素是全球抗感染药物市场上的一个重要分支,是在头孢类抗生素之后全球抗感染市场用药量最大的药物。

值得关注的是,这已经是今年FDA第二次发布针对此款药品的警戒说明。2016年5月12日,FDA发布公告,限制氟喹诺酮适应症并警告致残风险,提示急性鼻窦炎、急性支气管炎和单纯性尿路感染的患者在有其他治疗选择的情况下,使用氟喹诺酮类抗菌药品治疗引发相关严重不良反应的风险通常大于效益。针对上述疾病,氟喹诺酮类药品应该仅用于那些没有其他方案可供选择的患者。6月30日,CFDA转载了这个消息。

7月26日,FDA针对氟喹诺酮类抗菌药品再次发布发布公告,更新了药品说明书,警示了这些药物新的风险,同时还将这些这些风险放入了黑框警告。

药品安全性警示内容可以放在药品说明书中的[不良反应]、[禁忌]、[注意事项]项,黑框警告是美国FDA采取的最严重的警告形式,引人注目。

目前FDA批准的全身性治疗用的氟喹诺酮类药品列表



看着FDA列出的这些药品名单,很多都是大家耳熟能详的品种,还是销售额比较大的品种。据国内22个城市样本医院数据,国内抗感染类药物市场规模从2005年的85.2亿元增长到2014年的222.2亿元。 2014年,前10位抗感染类产品中喹诺酮类2个,左氧氟沙星7.5亿元,莫西沙星6.5亿元,增长率分别为7.9%和17.2%。 

存在不少严重问题,但这些疾病仍可使用

2016年7月26日,美国食品药品监督管理局(FDA)批准更新全身用氟喹诺酮类(即口服或注射给药)抗菌药物的说明书,警示这些药物与发生肌腱、肌肉、关节、神经和中枢神经系统的致残性永久性副作用相关,这些副作用可同时发生在同一患者身上。FDA将上述风险更新至说明书的黑框警告中,以警示这些严重安全性问题,同时也更新了说明书的警告、注意事项以及用药指南部分。目前美国上市的氟喹诺酮类药物包括莫西沙星、环丙沙星、吉米沙星、左氧氟沙星、氧氟沙星。

此次说明书修订之前,氟喹诺酮类抗菌药物的说明书中已有关于肌腱炎、肌腱断裂以及重症肌无力加重的黑框警告,还包括关于外周神经病变和中枢神经系统作用风险的警告。氟喹诺酮类抗菌药物导致的其他严重风险在说明书中均有描述,如心脏、皮肤及超敏反应。

继FDA于2013年经过评估增加了不可逆外周神经病变的警告之后,FDA又评估了相对健康的患者接受全身用氟喹诺酮类抗菌药物治疗后发生两个或多个系统的致残性永久性副作用的上市后报告。

由于急性细菌性鼻窦炎、慢性支气管炎急性加重及非复杂性尿路感染患者使用氟喹诺酮类抗菌药物的严重不良反应风险通常超过患者的获益,FDA认为上述适应证仅在无其他治疗方案时可使用氟喹诺酮类抗菌药物。对于某些严重细菌性感染,氟喹诺酮类抗菌药物的获益依然大于风险,该类药物仍可继续作为一种治疗选择。

患者使用氟喹诺酮类抗菌药物期间如发生任何严重副作用,请立即联系医务人员。严重副作用的体征和症状包括不常见的关节或肌腱疼痛、肌无力、“针刺样”刺痛感、四肢麻木、意识模糊和幻觉等。医务人员不得为可选择其他治疗方案的急性细菌性鼻窦炎、慢性支气管炎急性恶化以及非复杂性尿路感染患者处方全身用氟喹诺酮类抗菌药物,因其在这些患者中的风险超过了获益。如果患者报告了严重不良反应,必须立即停止氟喹诺酮类抗菌药物的治疗,改用非氟喹诺酮类抗菌药物完成患者疗程。

史上最严限抗令、安全问题频被提示

抗生素此前曾经有过疯狂时代,此前一位业内人士介绍说,一个东北某市级医院,一个抗生素品种一个月的用量就达到4万支;某个品种在一东北某省只做二级以下的医院,市场疯狂到每个月销售1000件货,每件货是5000支。

限抗令出台后,加上媒体一直宣传,抗生素市场开始出现了转折点。例如,一款产品以前每年销售额底价只少2个亿,今年已经少了6000万,很多做抗生素起家的大佬,或者转型,或者套现退出。

去年,非常罕见的,国家食品药品监督管理总局发布第六十九期《药品不良反应信息通报》,提示关注注射用头孢硫脒引起的过敏性休克及儿童用药风险。当天下午,央视整点新闻做了一分多钟的报道。

此次国家食药监总局紧跟FDA再次对氟喹诺酮类抗菌药物的警戒信息进行了转载,虽然这是转载的信息,对于医务人员的用药进行提醒,但是在药品安全备受关注,FDA接连两次对药物安全发布公告的情况,该品种近年来的增势恐怕难以持续。

本次审查概述
本次安全审查的目的是从科学文献中寻找自2012年审查结束后出现的关于使用质子泵抑制剂与艰难梭菌感染风险方面的新信息。艰难梭菌感染可造成轻度腹泻或危及生命的多器官衰竭,特别是有其他原患疾病的老年患者。加拿大卫生部于2009年开始对这一安全问题进行监测,2010年所有质子泵抑制剂的处方信息均已进行了更新,告知公众这些药物可能为艰难梭菌感染的风险因素。2012年,加拿大卫生部开展了一次随访评估并发布了公告,告知公众质子泵抑制剂可能对艰难梭菌感染的总体风险造成影响。

安全审查结果
本次审查前,加拿大卫生部共收到10份质子泵抑制剂使用患者发生艰难梭菌感染的报告。这些报告中,2份为2012年审查结束之后所接收的报告。本次审查开始前,加拿大卫生部对世界卫生组织数据库进行检索,检索到233份使用质子泵抑制剂患者发生艰难梭菌感染的报告。考虑到这些药物在加拿大和国外应用范围广泛,报告数量可能偏低。
多份科学文献报告描述了使用质子泵抑制剂与艰难梭菌感染和/或复发之间存在潜在关联性。然而,这些研究中的患者存在其他已知的艰难梭菌感染的风险因素。

结论与行动
加拿大卫生部的安全审查结论认为,现有证据太少,无法明确质子泵抑制剂是否直接诱发了艰难梭菌感染。目前的质子泵抑制剂处方信息反映了质子泵抑制剂使用患者发生艰难梭菌感染的可能性略高。由于潜在关联性无法排除,因此将更新处方信息以提供更多关于各种风险因素的信息。同时更新的处方信息将提醒医务人员和患者,这些药物的使用应保持最低剂量水平,并针对所治疗疾病制定相应最短的疗程。

医务人员
应意识到使用推荐剂量以上的洛哌丁胺可导致严重的心脏不良事件。洛哌丁胺可能是导致原因不明的包括QT间期延长、尖端扭转型室性心动过速或其它室性心律失常、晕厥和心跳骤停在内的一系列心脏事件的可能诱因。就药物滥用而言,患者经常同时服用其他药物,以求增加洛哌丁胺的吸收度并透过血脑屏障抑制洛哌丁胺的代谢以增强欣快感。如果发生疑似洛哌丁胺毒性反应,应立即停药并启动必要治疗。如果怀疑摄入了洛哌丁胺,可能需要进行特殊检测来测量血药浓度。对于一些药物治疗无效的尖端扭转型室性心动过速病例,可能需要行电起搏或电复律。应告知服用洛哌丁胺的患者须遵循说明书上的推荐剂量,服用剂量如果超过推荐剂量,无论是有意的或是无意的,均可导致异常心律及严重的致死性心脏事件。还应告知患者,洛哌丁胺与常用药物之间的药物相互作用,也会增大诱发严重心脏不良事件的风险。应为鸦片使用障碍患者提供适当治疗。

患者与消费者
应在医务人员指导下或按照OTC药物标签服用洛哌丁胺。服用剂量切勿超过处方剂量或标签剂量,否则会诱发严重的心律问题或死亡。如果腹泻时间持续超过了2天,应停止服用洛哌丁胺并联系医生。如果服用洛哌丁胺后出现了以下任何一种状况,需立即就医:
•昏厥
  •心搏加快或心律不规则
  •无反应,即患者叫不醒或患者应答或反应异常
  如果不能确定服用洛哌丁胺的准确剂量、服药频率或者服用的某种药物是否会与洛哌丁胺发生相互作用,请咨询药剂师或医护人员。告诉医护人员服用的所有药物,包括OTC药物。
可能会与洛派丁胺发生相互作用的药品示例
药品通用名 药品商品名示例
西咪替丁 Tagamet HB
克拉霉素 Biaxin, Prevpac
红霉素 E.E.S., Ery-Tab, Eryc, Eryped, PCE
吉非罗齐 Lopid
伊曲康唑 Onmel, Sporanox
酮康唑 仅有仿制药出售
奎尼丁 Nuedexta
奎宁 Qualaquin
雷尼替丁 Zantac
利托那韦 Kaletra, Norvir, Technivie, Viekira Pak


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=319594, encodeId=aed4319594b3, content=越来越觉得.用药需要考虑的东西太多, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/AicRibibwhnWAW33YRia7y5sicGOoEzFQ4Jzmt3N9mtq1lZOXghRysQ33pzibKOXyQUuTpZSGsEeyicy1zX75nRB1yuaQ/132, createdBy=5e942360447, createdName=foxv3羽翼, createdTime=Tue May 29 07:40:24 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=144426, encodeId=d1e214442606, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 15:09:53 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530092, encodeId=ac73153009203, content=<a href='/topic/show?id=7f7848124f5' target=_blank style='color:#2F92EE;'>#左氧氟沙星#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48124, encryptionId=7f7848124f5, topicName=左氧氟沙星)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=666412016730, createdName=cqlidoudou, createdTime=Thu Sep 15 01:42:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126224, encodeId=7f3712622454, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 09:38:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126053, encodeId=409e1260536a, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 08:11:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=125475, encodeId=fac51254e5d6, content=好好学习,争取改善。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170701/IMG595791009FB761316.jpg, createdBy=abd01695121, createdName=吴教授, createdTime=Tue Sep 13 16:04:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=125120, encodeId=a51912512066, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Sep 13 12:12:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=124624, encodeId=68b212462491, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 13 10:58:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=124629, encodeId=4bf612462959, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 13 10:58:00 CST 2016, time=2016-09-13, status=1, ipAttribution=)]
    2018-05-29 foxv3羽翼

    越来越觉得.用药需要考虑的东西太多

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=319594, encodeId=aed4319594b3, content=越来越觉得.用药需要考虑的东西太多, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/AicRibibwhnWAW33YRia7y5sicGOoEzFQ4Jzmt3N9mtq1lZOXghRysQ33pzibKOXyQUuTpZSGsEeyicy1zX75nRB1yuaQ/132, createdBy=5e942360447, createdName=foxv3羽翼, createdTime=Tue May 29 07:40:24 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=144426, encodeId=d1e214442606, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 15:09:53 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530092, encodeId=ac73153009203, content=<a href='/topic/show?id=7f7848124f5' target=_blank style='color:#2F92EE;'>#左氧氟沙星#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48124, encryptionId=7f7848124f5, topicName=左氧氟沙星)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=666412016730, createdName=cqlidoudou, createdTime=Thu Sep 15 01:42:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126224, encodeId=7f3712622454, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 09:38:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126053, encodeId=409e1260536a, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 08:11:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=125475, encodeId=fac51254e5d6, content=好好学习,争取改善。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170701/IMG595791009FB761316.jpg, createdBy=abd01695121, createdName=吴教授, createdTime=Tue Sep 13 16:04:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=125120, encodeId=a51912512066, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Sep 13 12:12:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=124624, encodeId=68b212462491, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 13 10:58:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=124629, encodeId=4bf612462959, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 13 10:58:00 CST 2016, time=2016-09-13, status=1, ipAttribution=)]
    2016-10-11 1e10c84am36(暂无匿称)

    好文章,受益

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=319594, encodeId=aed4319594b3, content=越来越觉得.用药需要考虑的东西太多, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/AicRibibwhnWAW33YRia7y5sicGOoEzFQ4Jzmt3N9mtq1lZOXghRysQ33pzibKOXyQUuTpZSGsEeyicy1zX75nRB1yuaQ/132, createdBy=5e942360447, createdName=foxv3羽翼, createdTime=Tue May 29 07:40:24 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=144426, encodeId=d1e214442606, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 15:09:53 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530092, encodeId=ac73153009203, content=<a href='/topic/show?id=7f7848124f5' target=_blank style='color:#2F92EE;'>#左氧氟沙星#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48124, encryptionId=7f7848124f5, topicName=左氧氟沙星)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=666412016730, createdName=cqlidoudou, createdTime=Thu Sep 15 01:42:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126224, encodeId=7f3712622454, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 09:38:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126053, encodeId=409e1260536a, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 08:11:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=125475, encodeId=fac51254e5d6, content=好好学习,争取改善。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170701/IMG595791009FB761316.jpg, createdBy=abd01695121, createdName=吴教授, createdTime=Tue Sep 13 16:04:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=125120, encodeId=a51912512066, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Sep 13 12:12:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=124624, encodeId=68b212462491, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 13 10:58:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=124629, encodeId=4bf612462959, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 13 10:58:00 CST 2016, time=2016-09-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=319594, encodeId=aed4319594b3, content=越来越觉得.用药需要考虑的东西太多, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/AicRibibwhnWAW33YRia7y5sicGOoEzFQ4Jzmt3N9mtq1lZOXghRysQ33pzibKOXyQUuTpZSGsEeyicy1zX75nRB1yuaQ/132, createdBy=5e942360447, createdName=foxv3羽翼, createdTime=Tue May 29 07:40:24 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=144426, encodeId=d1e214442606, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 15:09:53 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530092, encodeId=ac73153009203, content=<a href='/topic/show?id=7f7848124f5' target=_blank style='color:#2F92EE;'>#左氧氟沙星#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48124, encryptionId=7f7848124f5, topicName=左氧氟沙星)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=666412016730, createdName=cqlidoudou, createdTime=Thu Sep 15 01:42:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126224, encodeId=7f3712622454, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 09:38:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126053, encodeId=409e1260536a, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 08:11:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=125475, encodeId=fac51254e5d6, content=好好学习,争取改善。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170701/IMG595791009FB761316.jpg, createdBy=abd01695121, createdName=吴教授, createdTime=Tue Sep 13 16:04:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=125120, encodeId=a51912512066, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Sep 13 12:12:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=124624, encodeId=68b212462491, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 13 10:58:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=124629, encodeId=4bf612462959, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 13 10:58:00 CST 2016, time=2016-09-13, status=1, ipAttribution=)]
    2016-09-14 1dd8a7c5m95(暂无匿称)

    学习了,赞一个!!!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=319594, encodeId=aed4319594b3, content=越来越觉得.用药需要考虑的东西太多, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/AicRibibwhnWAW33YRia7y5sicGOoEzFQ4Jzmt3N9mtq1lZOXghRysQ33pzibKOXyQUuTpZSGsEeyicy1zX75nRB1yuaQ/132, createdBy=5e942360447, createdName=foxv3羽翼, createdTime=Tue May 29 07:40:24 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=144426, encodeId=d1e214442606, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 15:09:53 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530092, encodeId=ac73153009203, content=<a href='/topic/show?id=7f7848124f5' target=_blank style='color:#2F92EE;'>#左氧氟沙星#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48124, encryptionId=7f7848124f5, topicName=左氧氟沙星)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=666412016730, createdName=cqlidoudou, createdTime=Thu Sep 15 01:42:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126224, encodeId=7f3712622454, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 09:38:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126053, encodeId=409e1260536a, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 08:11:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=125475, encodeId=fac51254e5d6, content=好好学习,争取改善。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170701/IMG595791009FB761316.jpg, createdBy=abd01695121, createdName=吴教授, createdTime=Tue Sep 13 16:04:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=125120, encodeId=a51912512066, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Sep 13 12:12:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=124624, encodeId=68b212462491, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 13 10:58:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=124629, encodeId=4bf612462959, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 13 10:58:00 CST 2016, time=2016-09-13, status=1, ipAttribution=)]
    2016-09-14 1dd8a7c5m95(暂无匿称)

    学习了,赞一个!!!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=319594, encodeId=aed4319594b3, content=越来越觉得.用药需要考虑的东西太多, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/AicRibibwhnWAW33YRia7y5sicGOoEzFQ4Jzmt3N9mtq1lZOXghRysQ33pzibKOXyQUuTpZSGsEeyicy1zX75nRB1yuaQ/132, createdBy=5e942360447, createdName=foxv3羽翼, createdTime=Tue May 29 07:40:24 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=144426, encodeId=d1e214442606, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 15:09:53 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530092, encodeId=ac73153009203, content=<a href='/topic/show?id=7f7848124f5' target=_blank style='color:#2F92EE;'>#左氧氟沙星#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48124, encryptionId=7f7848124f5, topicName=左氧氟沙星)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=666412016730, createdName=cqlidoudou, createdTime=Thu Sep 15 01:42:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126224, encodeId=7f3712622454, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 09:38:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126053, encodeId=409e1260536a, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 08:11:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=125475, encodeId=fac51254e5d6, content=好好学习,争取改善。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170701/IMG595791009FB761316.jpg, createdBy=abd01695121, createdName=吴教授, createdTime=Tue Sep 13 16:04:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=125120, encodeId=a51912512066, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Sep 13 12:12:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=124624, encodeId=68b212462491, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 13 10:58:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=124629, encodeId=4bf612462959, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 13 10:58:00 CST 2016, time=2016-09-13, status=1, ipAttribution=)]
    2016-09-13 吴教授

    好好学习,争取改善。

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=319594, encodeId=aed4319594b3, content=越来越觉得.用药需要考虑的东西太多, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/AicRibibwhnWAW33YRia7y5sicGOoEzFQ4Jzmt3N9mtq1lZOXghRysQ33pzibKOXyQUuTpZSGsEeyicy1zX75nRB1yuaQ/132, createdBy=5e942360447, createdName=foxv3羽翼, createdTime=Tue May 29 07:40:24 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=144426, encodeId=d1e214442606, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 15:09:53 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530092, encodeId=ac73153009203, content=<a href='/topic/show?id=7f7848124f5' target=_blank style='color:#2F92EE;'>#左氧氟沙星#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48124, encryptionId=7f7848124f5, topicName=左氧氟沙星)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=666412016730, createdName=cqlidoudou, createdTime=Thu Sep 15 01:42:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126224, encodeId=7f3712622454, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 09:38:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126053, encodeId=409e1260536a, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 08:11:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=125475, encodeId=fac51254e5d6, content=好好学习,争取改善。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170701/IMG595791009FB761316.jpg, createdBy=abd01695121, createdName=吴教授, createdTime=Tue Sep 13 16:04:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=125120, encodeId=a51912512066, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Sep 13 12:12:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=124624, encodeId=68b212462491, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 13 10:58:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=124629, encodeId=4bf612462959, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 13 10:58:00 CST 2016, time=2016-09-13, status=1, ipAttribution=)]
    2016-09-13 忠诚向上

    好好学习一下

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=319594, encodeId=aed4319594b3, content=越来越觉得.用药需要考虑的东西太多, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/AicRibibwhnWAW33YRia7y5sicGOoEzFQ4Jzmt3N9mtq1lZOXghRysQ33pzibKOXyQUuTpZSGsEeyicy1zX75nRB1yuaQ/132, createdBy=5e942360447, createdName=foxv3羽翼, createdTime=Tue May 29 07:40:24 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=144426, encodeId=d1e214442606, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 15:09:53 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530092, encodeId=ac73153009203, content=<a href='/topic/show?id=7f7848124f5' target=_blank style='color:#2F92EE;'>#左氧氟沙星#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48124, encryptionId=7f7848124f5, topicName=左氧氟沙星)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=666412016730, createdName=cqlidoudou, createdTime=Thu Sep 15 01:42:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126224, encodeId=7f3712622454, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 09:38:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126053, encodeId=409e1260536a, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 08:11:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=125475, encodeId=fac51254e5d6, content=好好学习,争取改善。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170701/IMG595791009FB761316.jpg, createdBy=abd01695121, createdName=吴教授, createdTime=Tue Sep 13 16:04:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=125120, encodeId=a51912512066, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Sep 13 12:12:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=124624, encodeId=68b212462491, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 13 10:58:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=124629, encodeId=4bf612462959, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 13 10:58:00 CST 2016, time=2016-09-13, status=1, ipAttribution=)]
    2016-09-13 doctorJiangchao

    继续学习

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=319594, encodeId=aed4319594b3, content=越来越觉得.用药需要考虑的东西太多, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/AicRibibwhnWAW33YRia7y5sicGOoEzFQ4Jzmt3N9mtq1lZOXghRysQ33pzibKOXyQUuTpZSGsEeyicy1zX75nRB1yuaQ/132, createdBy=5e942360447, createdName=foxv3羽翼, createdTime=Tue May 29 07:40:24 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=144426, encodeId=d1e214442606, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 15:09:53 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530092, encodeId=ac73153009203, content=<a href='/topic/show?id=7f7848124f5' target=_blank style='color:#2F92EE;'>#左氧氟沙星#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48124, encryptionId=7f7848124f5, topicName=左氧氟沙星)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=666412016730, createdName=cqlidoudou, createdTime=Thu Sep 15 01:42:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126224, encodeId=7f3712622454, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 09:38:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126053, encodeId=409e1260536a, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 08:11:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=125475, encodeId=fac51254e5d6, content=好好学习,争取改善。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170701/IMG595791009FB761316.jpg, createdBy=abd01695121, createdName=吴教授, createdTime=Tue Sep 13 16:04:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=125120, encodeId=a51912512066, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Sep 13 12:12:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=124624, encodeId=68b212462491, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 13 10:58:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=124629, encodeId=4bf612462959, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 13 10:58:00 CST 2016, time=2016-09-13, status=1, ipAttribution=)]
    2016-09-13 doctorJiangchao

    继续关注

    0

相关资讯

FDA针对氟喹诺酮发出安全警告,限制其使用

FDA发出安全警报:治疗鼻窦炎、支气管炎、单纯性尿路感染时,只有在没有其他可供选择方案的情况下,才能使用氟喹诺酮类药物,因为该药物相关的不良事件风险超过了药物带来的益处。FDA在安全审查中发现氟喹诺酮类药物(片剂、胶囊和注射剂)可能存在肌腱、肌肉、关节、神经和中枢神经系统的致残性和潜在的永久性不良反应。FDA要求所有氟喹诺酮类药物标签和用药指南更新指定的信息。如果患者出现诸如肌腱疼痛、关节疼痛、肌

FDA再发警告,限制喹诺酮的使用,细数其罪状!

在医院实习那会儿,氟喹诺酮类药物用的那可是叫一个多啊,各种沙星天天都在用(诺氟沙星、培氟沙星、依诺沙星、氧氟沙星、环丙沙星......)。偶然间看到前几天FDA发布的对氟喹诺酮的安全警告,限制其使用,于是问了几个医生小盆友,哎哟喂,现在医院氟喹诺酮类药物用的也不少啊,于是心里咯噔了一下,对近几年著名机构或研究发布的关于氟喹诺酮类药物严重不良反应的警告进行了总结,希望大家能牢

诺酮类药物市场持续降温:3品种下滑明显,左氧氟沙星潜力犹存

近日,美国食品药品监督管理局(FDA)发布通告,提示急性鼻窦炎、急性支气管炎和单纯性尿路感染药物治疗时,氟喹诺酮类药品抗菌治疗引发相关严重不良反应的风险通常大于效益。氟喹诺酮类药物是20世纪80年代新兴的一类抗菌剂。尤其对需氧革兰氏阴性菌有较强灭菌作用,对金黄色葡萄球菌等革兰氏阳性菌也有较好的抗菌活性,某些品种对结核分枝杆菌、支原体、衣原体及厌氧菌具有良好的活性机制。进入2010年全世

FDA黑框警告!氟喹诺酮类药品需慎用!

2016年7月26日,FDA批准更新氟喹诺酮类药物(包括口服制剂和注射液)的药品标签。氟喹诺酮类药物全身用药时致残性和潜在的永久性严重不良反应可同时发生,这些不良反应累及肌腱、肌肉、关节、神经和中枢神经系统,因此FDA不但修订了黑框警告,特别强调用药的安全性问题,此外FDA还增加了新的警告,且同步更新了药品标签中用药指南等其他内容。此次FDA更新了氟喹诺酮类药品标签中的黑框警告,并增加了新的警告,

盘点:氟喹诺酮的功与过

喹诺酮类药物(4-quinolones),又称吡酮酸类或吡啶酮酸类,是一类较新的合成抗菌药。这类药物抗菌谱广、抗菌力强、口服吸收好,组织浓度高,与其他抗菌药物无交叉耐药性,不良反应相对较少等特点,已经成为治疗细菌感染性疾病的主要药物。 最早应用的如萘啶酸(nalidixic acid)和吡哌酸(pipemidic acid),仅用于泌尿道和肠道感染,因疗效差、耐药性发展迅速,应用日趋

FDA发警告!左氧到底还能不能用?

2016年7月26日,FDA批准更新氟喹诺酮类药物(包括口服制剂和注射液)的药品标签。氟喹诺酮类药物全身用药时致残性和潜在的永久性严重不良反应可同时发生,这些不良反应累及肌腱、肌肉、关节、神经和中枢神经系统,因此FDA不但修订了黑框警告,特别强调用药的安全性问题,此外FDA还增加了新的警告,且同步更新了药品标签中用药指南等其他内容。此次FDA更新了氟喹诺酮类药品标签中的黑框警告,并增加了新的警告,